Ge Minghao, Yang Runze, Xu Baojun, Fan Lei, Xu Maosen, Xu Tianhao, Li Jian, Li Yusheng, Gong Meng, Fu Weili
Sports Medicine Center, Department of Orthopedic Surgery/Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
BMC Med. 2025 Sep 1;23(1):513. doi: 10.1186/s12916-025-04358-7.
Pigmented villonodular synovitis (PVNS), or tenosynovial giant cell tumor (TGCT), is a locally aggressive soft tissue tumor primarily affecting the synovium of joints, particularly the knee. In PVNS, the synovial tissue thickens and becomes aggressive, leading to joint destruction, a process reminiscent of the tissue remodeling seen in autoimmune diseases. Despite being considered benign, PVNS often leads to severe joint damage and has a high recurrence rate following treatment. The underlying molecular mechanisms of PVNS remain poorly understood, necessitating further research to uncover its pathogenesis and identify potential therapeutic targets. This study aims to investigate the pathological mechanisms of PVNS, focusing on the role of metabolic pathways, immune cell infiltration, and osteoclast differentiation in the progression of the disease.
Synovial fluid samples from PVNS patients were subjected to high-throughput proteomic and metabolomic analyses. Differentially expressed proteins (DEPs) and metabolites were identified, and pathway enrichment analysis was performed. Western blot validation and two-way orthogonal partial least squares (O2PLS) analysis confirmed key findings and explored the relationships among identified biomarkers.
A total of 156 DEPs and 62 differential metabolites were identified. The "Osteoclast differentiation signalling" and "Nuclear factor-κB (NF-κB) survival signalling" pathways were significantly upregulated in PVNS samples, with Tumor Necrosis Factor Superfamily Member 11 (TNFSF11), Cathepsin K (CTSK), Adhesion G Protein-Coupled Receptor E5 (ADGRE5), and NF-κB showing marked increases in expression. Metabolomic analysis revealed that "Linoleic acid metabolism" and "Biosynthesis of unsaturated fatty acids" pathways were enhanced in PVNS, with metabolites such as 13-L-Hydroperoxylinoleic acid and 13-OxoODE being highly expressed. Western blot validation confirmed the elevated levels of ADGRE5, TNFSF11, CTSK, and NF-κB, suggesting a link between enhanced energy metabolism, lipid oxidation, and osteoclast differentiation. CONCLUSIONS: This study highlights the critical role of metabolic adaptations and immune cell activity in the progression of PVNS. The findings suggest that targeting ADGRE5 and NF-κB could offer new therapeutic strategies for controlling disease progression and reducing joint destruction in PVNS patients. Further research is needed to elucidate this disease's specific regulatory mechanisms and cell types.
色素沉着绒毛结节性滑膜炎(PVNS),又称腱鞘巨细胞瘤(TGCT),是一种具有局部侵袭性的软组织肿瘤,主要影响关节滑膜,尤其是膝关节。在PVNS中,滑膜组织增厚并具有侵袭性,导致关节破坏,这一过程让人联想到自身免疫性疾病中所见的组织重塑。尽管PVNS被认为是良性的,但它常导致严重的关节损伤,且治疗后复发率很高。PVNS的潜在分子机制仍知之甚少,需要进一步研究以揭示其发病机制并确定潜在的治疗靶点。本研究旨在探讨PVNS的病理机制,重点关注代谢途径、免疫细胞浸润和破骨细胞分化在疾病进展中的作用。
对PVNS患者的滑液样本进行高通量蛋白质组学和代谢组学分析。鉴定差异表达蛋白(DEP)和代谢物,并进行通路富集分析。蛋白质印迹验证和双向正交偏最小二乘法(O2PLS)分析证实了关键发现,并探索了已鉴定生物标志物之间的关系。
共鉴定出156种DEP和62种差异代谢物。“破骨细胞分化信号传导”和“核因子κB(NF-κB)存活信号传导”通路在PVNS样本中显著上调,肿瘤坏死因子超家族成员11(TNFSF11)、组织蛋白酶K(CTSK)、粘附G蛋白偶联受体E5(ADGRE5)和NF-κB的表达明显增加。代谢组学分析显示,PVNS中“亚油酸代谢”和“不饱和脂肪酸生物合成”通路增强,13-L-氢过氧化亚油酸和13-氧代十八碳二烯酸等代谢物高表达。蛋白质印迹验证证实了ADGRE5、TNFSF11、CTSK和NF-κB水平升高,表明能量代谢增强、脂质氧化与破骨细胞分化之间存在联系。
本研究强调了代谢适应和免疫细胞活性在PVNS进展中的关键作用。研究结果表明,靶向ADGRE5和NF-κB可为控制PVNS患者的疾病进展和减少关节破坏提供新的治疗策略。需要进一步研究以阐明该疾病的具体调节机制和细胞类型。